vs
HomeTrust Bancshares, Inc.（HTB）与Vericel Corp（VCEL）财务数据对比。点击上方公司名可切换其他公司
Vericel Corp的季度营收约是HomeTrust Bancshares, Inc.的1.7倍（$92.9M vs $53.6M），Vericel Corp同比增速更快（23.3% vs 3.7%），HomeTrust Bancshares, Inc.自由现金流更多（$45.3M vs $12.8M），过去两年Vericel Corp的营收复合增速更高（34.6% vs 3.5%）
HomeTrust Bancshares, Inc.是总部位于美国北卡罗来纳州阿什维尔的银行控股公司，总资产达43亿美元，在北卡、南卡、佐治亚和田纳西州共设有33家网点，旗下拥有HomeTrust银行、Tryon联邦银行等七家社区银行。
Vericel Corp是一家美国上市生物制药企业，前身为1989年在密歇根州安娜堡成立的Aastrom Bio，2014年10月正式更为现名，专注于生物制药相关领域的研发与商业化运营。
HTB vs VCEL — 直观对比
营收规模更大
VCEL
是对方的1.7倍
$53.6M
营收增速更快
VCEL
高出19.6%
3.7%
自由现金流更多
HTB
多$32.5M
$12.8M
两年增速更快
VCEL
近两年复合增速
3.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $53.6M | $92.9M |
| 净利润 | — | $23.2M |
| 毛利率 | — | 78.7% |
| 营业利润率 | 37.0% | 24.1% |
| 净利率 | — | 25.0% |
| 营收同比 | 3.7% | 23.3% |
| 净利润同比 | — | 17.3% |
| 每股收益（稀释后） | $0.93 | $0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HTBVCEL
| Q4 25 | $53.6M | $92.9M | ||
| Q3 25 | $54.1M | $67.5M | ||
| Q2 25 | $54.4M | $63.2M | ||
| Q1 25 | $50.9M | $52.6M | ||
| Q4 24 | $51.7M | $75.4M | ||
| Q3 24 | $50.6M | $57.9M | ||
| Q2 24 | $50.6M | $52.7M | ||
| Q1 24 | $50.0M | $51.3M |
净利润HTBVCEL
| Q4 25 | — | $23.2M | ||
| Q3 25 | $16.5M | $5.1M | ||
| Q2 25 | $17.2M | $-553.0K | ||
| Q1 25 | $14.5M | $-11.2M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | $13.1M | $-901.0K | ||
| Q2 24 | $12.4M | $-4.7M | ||
| Q1 24 | $15.1M | $-3.9M |
毛利率HTBVCEL
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
营业利润率HTBVCEL
| Q4 25 | 37.0% | 24.1% | ||
| Q3 25 | 38.5% | 5.1% | ||
| Q2 25 | 40.1% | -3.2% | ||
| Q1 25 | 36.2% | -24.3% | ||
| Q4 24 | 35.4% | 24.5% | ||
| Q3 24 | 33.2% | -4.3% | ||
| Q2 24 | 31.3% | -11.5% | ||
| Q1 24 | 38.0% | -10.7% |
净利率HTBVCEL
| Q4 25 | — | 25.0% | ||
| Q3 25 | 30.5% | 7.5% | ||
| Q2 25 | 31.6% | -0.9% | ||
| Q1 25 | 28.5% | -21.4% | ||
| Q4 24 | — | 26.3% | ||
| Q3 24 | 25.9% | -1.6% | ||
| Q2 24 | 24.6% | -8.9% | ||
| Q1 24 | 30.1% | -7.5% |
每股收益（稀释后）HTBVCEL
| Q4 25 | $0.93 | $0.46 | ||
| Q3 25 | $0.95 | $0.10 | ||
| Q2 25 | $1.00 | $-0.01 | ||
| Q1 25 | $0.84 | $-0.23 | ||
| Q4 24 | $0.83 | $0.40 | ||
| Q3 24 | $0.76 | $-0.02 | ||
| Q2 24 | $0.73 | $-0.10 | ||
| Q1 24 | $0.88 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $324.7M | $137.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $600.7M | $354.6M |
| 总资产 | $4.5B | $488.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HTBVCEL
| Q4 25 | $324.7M | $137.5M | ||
| Q3 25 | $315.8M | $135.4M | ||
| Q2 25 | $297.2M | $116.9M | ||
| Q1 25 | $299.8M | $112.9M | ||
| Q4 24 | $279.2M | $116.2M | ||
| Q3 24 | $293.5M | $101.7M | ||
| Q2 24 | $294.2M | $102.5M | ||
| Q1 24 | $380.5M | $110.6M |
股东权益HTBVCEL
| Q4 25 | $600.7M | $354.6M | ||
| Q3 25 | $595.8M | $321.9M | ||
| Q2 25 | $579.3M | $306.8M | ||
| Q1 25 | $565.4M | $295.5M | ||
| Q4 24 | $551.8M | $292.0M | ||
| Q3 24 | $540.0M | $257.5M | ||
| Q2 24 | $523.6M | $243.0M | ||
| Q1 24 | $513.2M | $233.9M |
总资产HTBVCEL
| Q4 25 | $4.5B | $488.0M | ||
| Q3 25 | $4.6B | $453.3M | ||
| Q2 25 | $4.6B | $435.6M | ||
| Q1 25 | $4.6B | $424.6M | ||
| Q4 24 | $4.6B | $432.7M | ||
| Q3 24 | $4.6B | $390.4M | ||
| Q2 24 | $4.7B | $376.8M | ||
| Q1 24 | $4.7B | $356.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $49.5M | $15.0M |
| 自由现金流经营现金流 - 资本支出 | $45.3M | $12.8M |
| 自由现金流率自由现金流/营收 | 84.5% | 13.8% |
| 资本支出强度资本支出/营收 | 7.8% | 2.4% |
| 现金转化率经营现金流/净利润 | — | 0.65× |
| 过去12个月自由现金流最近4个季度 | $93.8M | $24.7M |
8季度趋势，按日历期对齐
经营现金流HTBVCEL
| Q4 25 | $49.5M | $15.0M | ||
| Q3 25 | $-11.3M | $22.1M | ||
| Q2 25 | $-8.8M | $8.2M | ||
| Q1 25 | $71.7M | $6.6M | ||
| Q4 24 | $45.4M | $22.2M | ||
| Q3 24 | $43.8M | $10.2M | ||
| Q2 24 | $5.9M | $18.5M | ||
| Q1 24 | $-9.0M | $7.2M |
自由现金流HTBVCEL
| Q4 25 | $45.3M | $12.8M | ||
| Q3 25 | $-12.0M | $19.5M | ||
| Q2 25 | $-10.2M | $81.0K | ||
| Q1 25 | $70.7M | $-7.6M | ||
| Q4 24 | $42.4M | $8.5M | ||
| Q3 24 | $43.1M | $-9.2M | ||
| Q2 24 | $5.7M | $1.8M | ||
| Q1 24 | $-9.6M | $-6.8M |
自由现金流率HTBVCEL
| Q4 25 | 84.5% | 13.8% | ||
| Q3 25 | -22.2% | 28.8% | ||
| Q2 25 | -18.7% | 0.1% | ||
| Q1 25 | 138.7% | -14.5% | ||
| Q4 24 | 82.0% | 11.2% | ||
| Q3 24 | 85.1% | -15.9% | ||
| Q2 24 | 11.2% | 3.4% | ||
| Q1 24 | -19.2% | -13.3% |
资本支出强度HTBVCEL
| Q4 25 | 7.8% | 2.4% | ||
| Q3 25 | 1.4% | 3.9% | ||
| Q2 25 | 2.5% | 12.9% | ||
| Q1 25 | 2.0% | 27.0% | ||
| Q4 24 | 5.9% | 18.3% | ||
| Q3 24 | 1.3% | 33.5% | ||
| Q2 24 | 0.5% | 31.8% | ||
| Q1 24 | 1.1% | 27.3% |
现金转化率HTBVCEL
| Q4 25 | — | 0.65× | ||
| Q3 25 | -0.68× | 4.35× | ||
| Q2 25 | -0.51× | — | ||
| Q1 25 | 4.93× | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | 3.34× | — | ||
| Q2 24 | 0.48× | — | ||
| Q1 24 | -0.60× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HTB
暂无分部数据
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
